Regulus Therapeutics (RGLS) EBITDA (2012 - 2025)
Regulus Therapeutics (RGLS) EBITDA from Dec 31, 2012 to Mar 31, 2025. The TTM Regulus Therapeutics (RGLS) EBITDA is -$51M. You can adjust inflation or export chart.
Annual EBITDA
Quarterly EBITDA
Regulus Therapeutics (RGLS) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +59.41% |
| 3 Years TTM | +21.89% |
| 5 Years TTM | +21.96% |
| 10 Years TTM | +1.23% |
| All Time TTM | +10.68% |
Annual EBITDA change of Regulus Therapeutics (RGLS)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$10M | -78.97% |
| 2024 | -$50M | +60.91% |
| 2023 | -$31M | +9.82% |
| 2022 | -$28M | +2.78% |
| 2021 | -$27M | +99.85% |
| 2020 | -$14M | -13.90% |
| 2019 | -$16M | -64.27% |
| 2018 | -$45M | -34.18% |
| 2017 | -$68M | -14.67% |
| 2016 | -$79M | +49.01% |
| 2015 | -$53M | +22.46% |
| 2014 | -$43M | +164.11% |
| 2013 | -$16M | +42.21% |
| 2012 | -$12M | N/A |